RR No. 7-2026: How the Senior Citizen Discount Deduction Is Now Shared

Revenue Regulations No. 7-2026, reported by multiple Philippine outlets on October 15, 2026, updates 2010-era BIR rules on how the mandatory 20% senior citizen discount on medicines is deducted when pharmaceutical companies split the cost along the supply chain. Manufacturers, distributors, wholesalers-retailers, and retailers may now enter formal burden-sharing agreements under Department of Health (DOH) guidelines — but each party’s income tax deduction is capped at its own negotiated share, not the full 20%.

Stop Guessing Who Deducts What — Track Shared Discounts FREE →

What does RR No. 7-2026 actually change? #

RR No. 7-2026 (also cited as RR No. 007-2026) does not touch the 20% senior citizen discount itself or the VAT exemption on the discounted sale — both remain exactly as they were. What it updates is the mechanics of Revenue Regulations No. 7-2010, the original rule implementing Republic Act No. 9994, for cases where more than one player in the pharmaceutical supply chain — manufacturer, distributor, wholesaler-retailer, or retailer — agrees to share the cost of the discount among themselves rather than letting it land entirely on the retailer that rings up the sale.

Before this RR, the deduction framework assumed a single seller absorbing the discount and deducting the full amount from its own gross income. In practice, drug manufacturers and distributors have long negotiated informal cost-sharing arrangements with retail pharmacies to cushion the retailer’s margin. RR No. 7-2026 gives that practice a formal tax basis, provided it follows DOH guidelines and the burden-sharing agreement is documented.

The RR names pharmaceutical retailers, manufacturers, distributors, wholesalers-retailers, and wholesalers as the parties eligible to enter burden-sharing agreements for the senior citizen discount on medicines. This is narrower than the general senior citizen discount rule covered in How Sellers Deduct the Senior Citizen and PWD Discount from Gross Income — RR No. 7-2026 is specific to the drug supply chain, where the discount cost is routinely split between the company that makes or distributes the medicine and the pharmacy that sells it to the senior.

If your business sits anywhere in that chain — a drug manufacturer negotiating rebates with retail chains, a wholesaler-retailer absorbing part of a discount passed down from a principal, or a retail pharmacy receiving a subsidy from a manufacturer to offset the discount — this regulation changes how you document and deduct your share. A retailer operating outside pharmaceuticals (a grocery, a restaurant, a bookstore) is unaffected; the general rule in RR No. 7-2010 and RR No. 5-2017 still governs single-seller deductions for those businesses.

What is the operative rule on the deduction cap? #

The core change is a hard cap: a party’s deductible expense from gross income cannot exceed its own contractual share of the discount under the burden-sharing agreement, even though the senior still receives the full 20% off at the point of sale. This prevents two or more parties in the same transaction from each deducting the full discount amount, which would overstate the aggregate deduction claimed across the supply chain relative to the actual 20% given up.

Because the official BIR-published text of RR No. 7-2026 could not be directly fetched from bir.gov.ph in the environment used to research this article, the quote below is sourced from secondary press reporting rather than a direct primary-document fetch. Readers should confirm the exact wording against the official RR No. 7-2026 PDF once accessible:

“The total deductible expense from gross income shall not exceed the portion corresponding to the claimant’s share under said agreement.” — Revenue Regulations No. 7-2026, as quoted by BusinessMirror

In plain terms: if a manufacturer and a retailer agree the manufacturer absorbs 60% of the discount cost and the retailer absorbs 40%, the manufacturer may deduct only its 60% share from its own gross income, and the retailer may deduct only its 40% share from its own gross income — not the full discount amount on either side.

Parties entering a burden-sharing agreement must document it according to DOH guidelines and furnish a copy of the agreement to the DOH, giving the deduction a paper trail that both the BIR and DOH can verify. Based on reporting on RR No. 7-2026, the regulation treats the agreement itself — not a unilateral internal allocation — as the basis for each party’s deduction limit, which means an undocumented or unfiled arrangement leaves a company unable to substantiate anything beyond what it can show was actually agreed and furnished to DOH.

Practically, finance and compliance teams in the pharma supply chain should expect to:

Put the sharing percentage or formula in writing between the contracting parties (manufacturer-distributor, distributor-retailer, or similar pairings).
Follow DOH’s prescribed format or guidelines for the agreement, since the RR ties eligibility to DOH compliance, not just a private contract.
Furnish DOH with a copy of the executed agreement.
Keep the agreement on file alongside sales records substantiating each discounted transaction, the same recordkeeping baseline described in How Sellers Deduct the Senior Citizen and PWD Discount from Gross Income.
Allocate the deduction in the books strictly according to the agreed share — not the full 20% — for each party claiming a portion.

Worked example: a 60/40 split between a distributor and a retailer #

A concrete allocation makes the deduction cap easier to apply than the abstract rule, so consider a fictional distributor and a fictional retail pharmacy that have a signed, DOH-compliant burden-sharing agreement splitting the senior discount cost 60/40.

Suppose MedSupply Distribution Corp. (fictional) and Wellness Plus Pharmacy (fictional) agree that MedSupply shoulders 60% of the senior citizen discount cost on a particular medicine line, with Wellness Plus absorbing the remaining 40%, under a written agreement filed with DOH.

A senior citizen buys maintenance medication with an undiscounted price of ₱5,000.
The mandatory 20% discount is ₱1,000, so the senior pays ₱4,000 at the counter (the VAT treatment of this sale is unchanged and is covered separately in VAT Exemption for Senior Citizens and PWDs).
Under the 60/40 burden-sharing agreement, MedSupply’s share of the ₱1,000 discount is ₱600, and Wellness Plus’s share is ₱400.
Wellness Plus reports its full, undiscounted ₱5,000 gross sale and separately deducts only ₱400 — its agreed share — as an itemized business expense. It cannot deduct the full ₱1,000.
MedSupply, which typically reimburses or rebates its agreed share back to Wellness Plus (or absorbs it through a pricing mechanism specified in the agreement), deducts only its ₱600 share from its own gross income, substantiated by the same agreement and corresponding records.
Neither party may deduct more than its documented share, and the two shares together should equal the ₱1,000 discount actually granted — not exceed it.

This cap matters most for groups with related distributor and retail entities, where, absent RR No. 7-2026’s documentation requirement, there would otherwise be room to double-count the same discount as a deduction on two sets of books.

Is the deduction still limited to itemized deductions? #

Yes — the burden-sharing deduction is available only to taxpayers using itemized deductions, consistent with the existing rule that senior citizen and PWD discount deductions are not available under the Optional Standard Deduction (OSD). A manufacturer, distributor, wholesaler-retailer, or retailer that elects OSD for the taxable year gives up the ability to separately deduct its share of the discount, because OSD already substitutes a flat percentage deduction for all itemized business expenses. Any party in a burden-sharing agreement that wants to claim its share under RR No. 7-2026 needs to be on itemized deductions for that year.

When does RR No. 7-2026 take effect? #

At least one news report states the regulation takes effect 15 days after its official publication, which is the standard effectivity clause used in most BIR revenue regulations — but this detail has not been independently confirmed against the primary BIR document in the research for this article. Companies in the pharmaceutical supply chain should treat the effectivity date as reported, not confirmed, and verify the exact date against the official published text or a BIR advisory once it is accessible, rather than assuming a specific calendar date from press coverage alone.

What should finance and compliance teams do now? #

Companies in the pharmaceutical manufacturing, distribution, wholesale, and retail chain should review existing informal discount-sharing arrangements and formalize them in writing under DOH guidelines before claiming any split deduction under RR No. 7-2026. Concretely:

Identify every existing arrangement where the senior citizen discount cost is informally split with another party in the supply chain.
Draft or update a written burden-sharing agreement that states each party’s exact percentage or peso share, aligned with DOH’s prescribed guidelines.
File a copy of the agreement with DOH as required.
Update internal expense-recognition policies so each entity’s books reflect only its own agreed share as the deductible amount — not the full discount.
Confirm with a tax professional that the entity’s deduction method (itemized vs. OSD) permits the claim at all.
Watch for the official BIR-published text of RR No. 7-2026 to confirm the exact effectivity date and any additional documentary requirements not yet reported in press coverage.

Summary #

RR No. 7-2026 leaves the 20% mandatory senior citizen discount and its VAT exemption untouched, but it formalizes how pharmaceutical manufacturers, distributors, wholesalers-retailers, and retailers may share the cost of that discount under DOH-guided burden-sharing agreements. The operative change is the deduction cap: each party may deduct only its own documented share of the discount from gross income, under itemized deductions only, substantiated by a written agreement furnished to DOH. Because the primary BIR text was not directly accessible during research, companies should confirm the exact effectivity date and full documentary requirements against the official published regulation, and consult a tax professional before restructuring any existing cost-sharing arrangement.

Sources: Inquirer.net — “BIR updates 2010 tax rules on shared drug discounts for seniors”, BusinessMirror — “BIR: Drug makers must share in SC discounts”.